Venous thromboembolism in association with features of the metabolic syndrome

被引:32
作者
Ray, J. G.
Lonn, E.
Yi, Q.
Rathe, A.
Sheridan, P.
Kearon, C.
机构
[1] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada
[2] Univ Toronto, St Michaels Hosp, Dept Obstet & Gynecol, Toronto, ON M5B 1W8, Canada
[3] Univ Toronto, St Michaels Hosp, Dept Hlth Policy Management & Evaluat, Toronto, ON M5B 1W8, Canada
[4] McMaster Univ, Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada
[5] McMaster Univ, Hamilton Gen Hosp, Dept Med, Hamilton, ON, Canada
[6] Hamilton Hlth Sci, Div Cardiol, Dept Med, Hamilton, ON, Canada
[7] Henderson Res Ctr, Hamilton, ON, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1093/qjmed/hcm083
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Central obesity, diabetes mellitus, dyslipidaemia and chronic hypertensionfeatures of the metabolic syndromehave been individually associated with venous thromboembolism (VTE). However, whether each of these factors additively increases the risk of VTE is uncertain. Aim: To determine whether features of the metabolic syndrome independently increase the risk of VTE. Design: Prospective cohort study derived from the Heart Outcomes Prevention Evaluation 2 (HOPE-2) randomized clinical trial. Setting: One hundred and forty-five clinical centres in 13 countries. Methods: We studied 5522 adults aged 55 years with cardiovascular disease or diabetes mellitus. At enrolment, 35 had 01 features of the metabolic syndrome, 30 had two, 24 had three and 11 had four. We defined symptomatic VTE as an objectively confirmed new episode of deep-vein thrombosis or pulmonary embolism. Results: VTE occurred in 88 individuals during a median 5.0 years of follow-up. The incidence rate of VTE (per 100 person-years) was 0.30 with 01 features, 0.36 with two features, 0.38 with three features and 0.40 with four features of the metabolic syndrome (trend p 0.43). Relative to the presence of 01 features of the metabolic syndrome, the adjusted hazard ratio (95CI) for VTE was 1.22 (0.712.08) with two features, 1.25 (0.702.24) with three features, and 1.26 (0.592.69) with four features. Discussion: The number of features of the metabolic syndrome present was not a clinically important risk factor for VTE in older adults with vascular arterial disease.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 12 条
[1]   The metabolic syndrome and the risk of venous thrombosis: a case-control study [J].
Ageno, W. ;
Prandoni, P. ;
Romualdi, E. ;
Ghirarduzzi, A. ;
Dentali, F. ;
Pesavento, R. ;
Crowther, M. ;
Venco, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (09) :1914-1918
[2]   Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study [J].
Canonico, M. ;
Oger, E. . ;
Conard, J. . ;
Meyer, G. ;
Levesque, H. ;
Trillot, N. ;
Barrellier, M. T. . ;
Wahl, D. ;
Emmerich, J. . ;
Scarabin, P. Y. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (06) :1259-1265
[3]   Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status [J].
Devaraj, S ;
Rosenson, RS ;
Jialal, I .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2004, 33 (02) :431-+
[4]   Smoking and abdominal obesity -: Risk factors for venous thromboembolism among middle-aged Men:: "The study of men born in 1913" [J].
Hansson, PO ;
Ericksson, H ;
Welin, L ;
Svärdsudd, K ;
Wilhelmsen, L .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (16) :1886-1890
[5]   Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients:: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial [J].
Lonn, E ;
Held, C ;
Arnold, JMO ;
Probstfield, J ;
McQueen, M ;
Micks, M ;
Pogue, J ;
Sheridan, P ;
Bosch, J ;
Genest, J ;
Yusuf, S ;
Lonn, E ;
Yusuf, S ;
Genest, J ;
Arnold, JMO ;
Avezum, A ;
Bosch, J ;
Choy, J ;
Dagenais, G ;
Davies, R ;
Fisher, M ;
Fodor, G ;
Hamalainen, T ;
Heyndrickx, G ;
Hoeschen, R ;
Klein, W ;
Kuritzky, R ;
Mann, J ;
McQueen, M ;
Micks, M ;
Mitchell, B ;
Ostergren, J ;
Piegas, L ;
Pogue, J ;
Probstfield, J ;
Sleight, P ;
Spinas, G ;
Sussex, B ;
Teo, K ;
Title, L ;
Tsuyuki, R ;
Arnold, JMO ;
Avezum, A ;
Arnold, A ;
Auger, P ;
Bata, I ;
Bernstein, V ;
Bourassa, M ;
Dagenais, G ;
Fodor, G .
CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (01) :47-53
[6]  
Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900
[7]   Endothelial dysfunction and the metabolic syndrome [J].
Gary E. McVeigh ;
Jay N. Cohn .
Current Diabetes Reports, 2003, 3 (1) :87-92
[8]   Metabolic syndrome and diabetic atherothrombosis: Implications in vascular complications [J].
Meerarani, P. ;
Badimon, J. J. ;
Zias, E. ;
Fuster, V. ;
Moreno, P. R. .
CURRENT MOLECULAR MEDICINE, 2006, 6 (05) :501-514
[9]   The risk of venous thromboembolism is markedly elevated in patients with diabetes [J].
Petrauskiene, V ;
Falk, M ;
Waernbaum, I ;
Norberg, M ;
Eriksson, J .
DIABETOLOGIA, 2005, 48 (05) :1017-1021
[10]   Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment [J].
Ray, JG .
CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (05) :378-384